Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.

doi:10.1155/2014/246171

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.

Journal of immunology research - 1 Jan 2014

Kunze-Schumacher Heike, Blasczyk Rainer, Bade-Doeding Christina

Abstract excerpt

HLA class I incompatibilities still remain one of the main barriers for unrelated bone marrow transplantation (BMT); hence the molecular understanding of how to mismatch patients and donors and still have successful clinical outcomes will guide towards the future of unrelated BMT. One way to estimate the magnitude of polymorphisms within the PBR is to determine which peptides can be selected by individual HLA...

Topics

Alleles
Bone Marrow Transplantation
Graft vs Host Disease
HLA Antigens
Histocompatibility Testing
Humans
Models, Immunological
Peptides
T-Lymphocytes
Unrelated Donors

Source

Open in PubMed Open full text

Identifiers

PMID: 25254222
DOI: 10.1155/2014/246171
PMCID: PMC4165401

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics